JP7386535B2 - 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 - Google Patents

単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 Download PDF

Info

Publication number
JP7386535B2
JP7386535B2 JP2020509054A JP2020509054A JP7386535B2 JP 7386535 B2 JP7386535 B2 JP 7386535B2 JP 2020509054 A JP2020509054 A JP 2020509054A JP 2020509054 A JP2020509054 A JP 2020509054A JP 7386535 B2 JP7386535 B2 JP 7386535B2
Authority
JP
Japan
Prior art keywords
hsv
another embodiment
composition
modified
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020509054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531465A5 (https=
JP2020531465A (ja
Inventor
ハーベイ フリードマン，
ドリュー ワイスマン，
シタ アワスティ，
ゲイリー コーエン，
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2020531465A publication Critical patent/JP2020531465A/ja
Publication of JP2020531465A5 publication Critical patent/JP2020531465A5/ja
Priority to JP2023138084A priority Critical patent/JP7674760B2/ja
Application granted granted Critical
Publication of JP7386535B2 publication Critical patent/JP7386535B2/ja
Priority to JP2025069088A priority patent/JP2025108645A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020509054A 2017-08-17 2018-08-17 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 Active JP7386535B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023138084A JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用
JP2025069088A JP2025108645A (ja) 2017-08-17 2025-04-18 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762546648P 2017-08-17 2017-08-17
US62/546,648 2017-08-17
US201862701019P 2018-07-20 2018-07-20
US62/701,019 2018-07-20
PCT/IB2018/056210 WO2019035066A1 (en) 2017-08-17 2018-08-17 MODIFIED MHRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023138084A Division JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用

Publications (3)

Publication Number Publication Date
JP2020531465A JP2020531465A (ja) 2020-11-05
JP2020531465A5 JP2020531465A5 (https=) 2021-09-24
JP7386535B2 true JP7386535B2 (ja) 2023-11-27

Family

ID=65362983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020509054A Active JP7386535B2 (ja) 2017-08-17 2018-08-17 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用
JP2023138084A Active JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用
JP2025069088A Pending JP2025108645A (ja) 2017-08-17 2025-04-18 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023138084A Active JP7674760B2 (ja) 2017-08-17 2023-08-28 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用
JP2025069088A Pending JP2025108645A (ja) 2017-08-17 2025-04-18 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用

Country Status (7)

Country Link
US (3) US11141478B2 (https=)
EP (2) EP4242223A3 (https=)
JP (3) JP7386535B2 (https=)
CN (2) CN111246854A (https=)
AU (2) AU2018316811B2 (https=)
CA (1) CA3073161A1 (https=)
WO (1) WO2019035066A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49463A (fr) * 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CN111246854A (zh) 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
BR112021018039A2 (pt) * 2019-03-12 2021-11-23 BioNTech SE Rna terapêutico para câncer de próstata
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法
EP4171629A1 (en) * 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
US12419948B2 (en) 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
EP4225360A1 (en) 2020-10-08 2023-08-16 Virothera Limited Vaccine compositions
EP4032546A1 (en) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutic viral vaccine
EP4032547A1 (en) * 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JP2024512394A (ja) 2021-03-11 2024-03-19 レッドバイオテック・アーゲー Ｈｓｖを処置するためのワクチン組成物及び方法
CN118217388A (zh) * 2022-12-19 2024-06-21 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用
EP4654996A1 (en) * 2023-01-27 2025-12-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein c, glycoprotein d, and glycoprotein e antigens and related methods
WO2024163918A1 (en) * 2023-02-02 2024-08-08 University Of Houston System Mrna vaccine for herpes simplex virus
WO2024249967A1 (en) * 2023-06-02 2024-12-05 The Trustees Of The University Of Pennsylvania Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2025030165A1 (en) * 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
IL326358A (en) 2023-08-03 2026-04-01 Univ Pennsylvania RNA compositions encoding herpes simplex virus glycoprotein E and/or glycoprotein I antigens and their uses
CN121843710A (zh) 2023-08-03 2026-04-10 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白b抗原的rna组合物及其用途
CN121772938A (zh) * 2023-08-03 2026-03-31 百欧恩泰欧洲股份公司 用于递送单纯疱疹病毒抗原的药物组合物及相关方法
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025109008A1 (en) 2023-11-20 2025-05-30 Redbiotec Ag Novel vaccine compositions and methods for treating hsv
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025175124A1 (en) * 2024-02-15 2025-08-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus glycoprotein b for treatment and prevention of herpes simplex virus infections
WO2025212831A1 (en) * 2024-04-03 2025-10-09 The Trustees Of The University Of Pennsylvania Methods of inducing an anti-hsv b-cell immune response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP3756684A1 (en) * 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
KR102136433B1 (ko) * 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
AU2014362234B2 (en) * 2013-12-11 2019-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
PE20170261A1 (es) * 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
WO2016049705A1 (en) * 2014-10-01 2016-04-07 Admedus Vaccines Pty Ltd Therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
US10758694B2 (en) 2015-07-09 2020-09-01 Hoyt Medical LLC Systems and methods for treating an airway using a tapered adapter device
US20180289792A1 (en) * 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
BR112019008481A2 (pt) * 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
MA49463A (fr) 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CN111246854A (zh) 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070623A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUBURU, N. et al.，J Virol，2015年，Vol. 89, No. 1，pp. 83-96
KARIKO, K. et al.，Mol Ther，2012年，Vol. 20, No. 5，pp. 948-953
KOBER, L. et al.，Biotechnol Bioeng，2013年，Vol. 110, No. 4，pp. 1164-1173
SCHLAKE, T. et al.，RNA Biol，2012年，Vol. 9, No. 11，pp. 1319-1330
ZHANG, L. et al.，J Gene Med，2005年，Vol. 7，pp. 354-365

Also Published As

Publication number Publication date
EP3668520A4 (en) 2021-05-12
US11141478B2 (en) 2021-10-12
US11793872B2 (en) 2023-10-24
JP7674760B2 (ja) 2025-05-12
JP2025108645A (ja) 2025-07-23
EP4242223A2 (en) 2023-09-13
US20210386853A1 (en) 2021-12-16
CN118370812A (zh) 2024-07-23
US20200276300A1 (en) 2020-09-03
CA3073161A1 (en) 2019-02-21
EP4242223A3 (en) 2024-03-13
CN111246854A (zh) 2020-06-05
AU2018316811B2 (en) 2023-07-13
JP2020531465A (ja) 2020-11-05
AU2018316811A1 (en) 2020-03-12
EP3668520A1 (en) 2020-06-24
AU2023248194A1 (en) 2023-11-02
WO2019035066A1 (en) 2019-02-21
US20240024463A1 (en) 2024-01-25
JP2023153423A (ja) 2023-10-17

Similar Documents

Publication Publication Date Title
JP7674760B2 (ja) 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用
US11510977B2 (en) Nucleic acid vaccines for coronavirus
JP2025037989A (ja) ヒトサイトメガロウイルスワクチン
US20230248818A1 (en) Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2
JP2025508332A (ja) 単純ヘルペスウイルス抗原の送達のための薬学的組成物及び関連方法
WO2023006062A1 (en) Nucleic acid vaccines for mutant coronavirus
WO2025030103A1 (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
US20240016922A1 (en) Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2024249967A1 (en) Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof
HK40100925A (en) Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
WO2025212831A1 (en) Methods of inducing an anti-hsv b-cell immune response
AU2024318951A1 (en) Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
WO2024245317A9 (en) Mutated fragment of vzv glycoprotein e
WO2024163918A1 (en) Mrna vaccine for herpes simplex virus
WO2026030275A1 (en) Rna molecules
WO2025255393A1 (en) Herpes simplex virus antigen binding agents for mitigation of herpes simplex virus associated disease
EP4366770A1 (en) P7 containing nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7386535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150